title: Interference of antibody production to hepatitis B surface antigen in a combination hepatitis A/hepatitis B vaccine.
abstract: A randomized trial comparing 3 manufacturing consistency lots of a combination hepatitis A/hepatitis B vaccine to each other and to hepatitis A vaccine and hepatitis B vaccine given separately and concurrently was done to evaluate safety, tolerability, and immunogenicity. Healthy volunteers >/=11 years of age were divided into 4 groups. Each of 3 groups received a separate consistency lot of the combination vaccine, and 1 group received separate but concurrent injections of hepatitis A and hepatitis B vaccines. Injections were given at weeks 0 and 24. The combination vaccine was generally well tolerated. The hepatitis A portion of the combination vaccine produced clinically acceptable high seropositivity rates 4 and 52 weeks after the first injection. The hepatitis B portion of the vaccine did not produce clinically acceptable seropositivity rates 4 weeks after the second injection. Lack of antibody production may be attributed, at least in part, to immunologic interference.
authors.affiliation: Saint Louis University Health Sciences Center, St. Louis, MO 63110, USA.
authors.forename: S
authors.initials: S
authors.lastname: Frey
authors.forename: R
authors.initials: R
authors.lastname: Dagan
authors.forename: Y
authors.initials: Y
authors.lastname: Ashur
authors.forename: X Q
authors.initials: XQ
authors.lastname: Chen
authors.forename: J
authors.initials: J
authors.lastname: Ibarra
authors.forename: H
authors.initials: H
authors.lastname: Kollaritsch
authors.forename: M H
authors.initials: MH
authors.lastname: Mazur
authors.forename: G A
authors.initials: GA
authors.lastname: Poland
authors.forename: K
authors.initials: K
authors.lastname: Reisinger
authors.forename: E
authors.initials: E
authors.lastname: Walter
authors.forename: P
authors.initials: P
authors.lastname: Van Damme
authors.forename: J H
authors.initials: JH
authors.lastname: Braconier
authors.forename: I
authors.initials: I
authors.lastname: Uhnoo
authors.forename: M
authors.initials: M
authors.lastname: Wahl
authors.forename: M M
authors.initials: MM
authors.lastname: Blatter
authors.forename: D
authors.initials: D
authors.lastname: Clements
authors.forename: D
authors.initials: D
authors.lastname: Greenberg
authors.forename: R M
authors.initials: RM
authors.lastname: Jacobson
authors.forename: S R
authors.initials: SR
authors.lastname: Norrby
authors.forename: M
authors.initials: M
authors.lastname: Rowe
authors.forename: D
authors.initials: D
authors.lastname: Shouval
authors.forename: S S
authors.initials: SS
authors.lastname: Simmons
authors.forename: J
authors.initials: J
authors.lastname: van Hattum
authors.forename: S
authors.initials: S
authors.lastname: Wennerholm
authors.forename: J O
authors.initials: JO
authors.lastname: Gress
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D005260:Female; D022362:Hepatitis A Vaccines; D006510:Hepatitis B Antibodies / Q000096:biosynthesis*; D006514:Hepatitis B Surface Antigens / Q000276:immunology*; D017325:Hepatitis B Vaccines / Q000008:administration & dosage / Q000276:immunology*; D006515:Hepatitis B virus / Q000276:immunology; D006507:Hepatovirus / Q000276:immunology; D006801:Humans; D008297:Male; D014611:Vaccination; D017778:Vaccines, Combined / Q000008:administration & dosage / Q000276:immunology*; D014761:Viral Hepatitis Vaccines / Q000008:administration & dosage / Q000276:immunology*
chemical_list: D022362:Hepatitis A Vaccines; D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D017778:Vaccines, Combined; D014761:Viral Hepatitis Vaccines